Project Grant R37CA291948
Award Date
6/1/25
Completion Date
5/31/30
Dollars Obligated
$598K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $666,670 Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of innovative scan protocols that combine long-axial field-of-view positron emission tomography (PET) and spectral computed tomography (CT) to enhance quantification capabilities for oncology applications. The key objectives are to: 1) develop spectral CT protocols and processing pipelines to generate dynamic iodine maps and perfusion data,...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $665,435 to The Leland Stanford Junior University to develop the first system capable of simultaneous multi-tracer Positron Emission Tomography (PET) imaging. The project aims to enable simultaneous imaging of multiple tracers by strategically choosing at least one PET tracer that emits gamma photons in cascade with their positron. This will allow differentiation of the...
This $399,829 federal Project Grant award from the National Cancer Institute's (NCI) Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to validate a positron emission tomography (PET) imaging approach to evaluate early response to antibody-drug conjugate (ADC) therapies in gastric cancer tumors. The primary objectives are to: 1) use PET imaging to investigate the role of the sphingosine-1-phosphate receptor (S1PR1) in ADC efficacy, and 2) determine the potential...
This National Cancer Institute (NCI) Project Grant award under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $554,188 to The Trustees of the University of Pennsylvania to develop and advance novel silver telluride nanoparticle contrast agents for improved breast cancer screening via dual-energy mammography. The project aims to adapt the nanoparticle synthesis for scalable production, characterize the particles' performance in breast cancer models, conduct safety...
The National Cancer Institute (NCI) awarded a $822,412 Project Grant under CFDA 93.394 - Cancer Detection and Diagnosis Research to The Leland Stanford Junior University to develop [18F]HGTS13, a novel radiopharmaceutical for non-invasive PET imaging of system xc- activity. The goal is to establish [18F]HGTS13 PET as a marker for monitoring drug-induced cancer ferroptosis, a form of regulated cell death, in cell culture and preclinical models. The project also aims to translate [18F]HGTS13 for...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) provides $505,848.59 to The Trustees of the University of Pennsylvania to develop new methods for rapidly accessing fluorine-18 labeled organic molecules for positron emission tomography (PET) imaging agents. The key objectives are to: 1) Optimize an amide C-H radiofluorination...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $402,401 to Emory University to develop a PET CCR2 imaging agent to profile the pancreatic ductal adenocarcinoma (PDAC) microenvironment. The funding period runs from July 4, 2024 to June 30, 2026. The project aims to create an innovative PET imaging agent capable of visualizing CCR2, a key molecular target associated with the PDAC tumor microenvironment. By profiling...
This federal Project Grant award, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286), aims to develop deep learning methods to improve gallium 68-based PET imaging for the management of neuroendocrine tumors and prostate cancer. The $442,037 award to the University of Florida will fund the development of a data-driven respiratory...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $295,000 to Theracea Pharma LC supports the development of innovative 18F-radiotracer kits for use in positron emission tomography (PET) imaging. The project aims to create advanced diagnostic tools to assist researchers and physicians, particularly in the field of oncology, by enabling more precise selection and assessment of cancer therapies, including immunotherapy. The...
This National Cancer Institute (NCI) Project Grant award (CFDA 93.396 Cancer Biology Research) provides $227,906 to develop a first-of-its-kind technology for spatially resolved multi-omics sequencing of formalin-fixed paraffin-embedded (FFPE) tumor tissue samples at the cellular level. Specifically, the award will: Develop spatial epigenome sequencing to measure gene expression and epigenetic profiles in FFPE tissues. Create a novel barcoding strategy to jointly profile accessible chromatin,...